It is well recognized that patients who have cancer have multiple defects in their immune-signalling/intercellular-communication pathways. Addressing these defects may destroy malignant growths as well as prevent their recurrence. Tumor-specific antigens and cytokines stimulate T-cells from cancer patients resulting in the generation of tumor-specific cytotoxic T lymphocytes. Cytokines have direct antitumor effects as well.